Boston Scientific Announces FDA Approval for the Latest-Generation WATCHMAN FLX ™ Pro Left Atrial Appendage Closure Device

Designed to further advance the procedural performance and safety of the WATCHMAN technology, which is indicated to reduce stroke risk in patients with non-valvular atrial fibrillation (NVAF) who need an alternative to oral anticoagulation therapy, the device now features a polymer coating, visualization markers and a broader size matrix to treat a wider range of patients.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news